PETALUMA, Calif., May 11, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products in multiple markets, today announced the company is preparing to initiate a double-blind, randomized clinical study evaluating an advanced Microcyn® hydrogel for management of hypertrophic or keloid scars under an FDA-reviewed protocol. The company plans to initiate the trial in the 2012 calendar year and would require approximately six months for completion. The study design calls for recruitment of up to 40 patients at three different U.S. sites, which are currently under review.
